10/11/2016
Thought leaders around the triangle are coming together for the upcoming 2-day ACRP RTP Chapter Fall Conference held at NC Biotechnology Center on Friday Oct 21 and Saturday Oct 22.
-
On September 8th, 2025, the US Food and Drug Administration (FDA) released their final guidance for industry on the ICH E6(R3) Good Clinical Practice (GCP). ICH E6(R3) Principles and Annex 1 were finalized on January 6th, 2025, officially taking over the preceding 2016 ICH E6(R2). Annex 2 is expected to be finalized in early 2026.
-
On December 15th, 2025, the US Food and Drug Administration (FDA) released the finalized guidance for industry “Investigator Responsibilities — Safety Reporting for Investigational Drugs and Devices”. Unlike most updates, this finalized guidance is replacing the FDA’s recommendations from two separate final guidance documents: “Safety Reporting Requirements for INDs and BA/BE Studies” from 2012 and “Adverse Event Reporting to IRBs—Improving Human Subject Protection” from 2009, both of which are now withdrawn.
-
On July 7, 2025, the European Union (EU) Commission and Pharmaceutical Inspection Co-operation Scheme (PIC/S) published an updated draft of Annex 11: Computerised Systems, a supplementary guideline that is part of the Good Manufacturing Practice (GMP). Although it is GMP focused, the guiding principles of the annex can also be applied to other GxP standards.
-
In July, 2025, the US Food and Drug Administration (FDA) issued a warning letter to an investigator conducting a clinical trial for pediatric participants. The warning letter was the result of a routine inspection part of the FDA’s Bioresearch Monitoring Program (BIMO) as well as the investigator’s written response to the Form FDA 483.
-
On August 27, 2025, the International Organization for Standardization (ISO) released a Draft International Standard (DIS) for the ISO 9001:2026 Quality Management Systems (QMS) to ISO member bodies for a twelve-week review and ballot period. The goal of ISO 9001 is to help organizations create and maintain consistency of their products or services and seeks to improve and refine their internal processes and procedures to increase efficiency.
Date: October 13, 2016
Time: 11:00 am EST | 15:00 GMT
Link: http://tinyurl.com/econsentwebinar
Our own SAM Sather and Mika Lindroos from CRF Health will discuss the important topic of regulatory risks in the informed consent process on this exciting upcoming webinar. As you know, Informed Consent is one of the most cited GCP deficiencies by regulatory authorities and contributes to increases in the risk of delayed approvals, litigation and yes, even trial failure.
According to the Office for Human Research Protections, the Common Rule, which began circulating in 1991, is undergoing an upgrade of sorts in order to ensure the better protection of human subjects involved in research conducted through clinical trials. The U.S. Department of Health and Human Services has propositioned the revision of the Federal Policy for the Protection of Human Subjects. The goal of the Common Rule’s revision would be to strengthen the overall policy through modernization and an increase and focus on efficiency.
Date: June 16, 2016
Time: 1:00pm-2:30pm, EDT US
Duration: 90 Minutes - Online
Course Link: http://www.lifesciencetraininginstitute.com/doc/monitoring-electronic-health-records-ehrs-0001
UPDATE: This course will include discussion of the NEW FDA Draft Guidance “Use of Electronic Health Record (EHR) data in Clinical Investigations”
June 14th, 2016, TOMORROW
11:00 am EDT | 16:00 GMT
Key processes within our industry have been in need of substantial change and improvement, one being the informed consent process.
Informed consent is still one of the most cited regulatory deficiencies, this along with the new technologies available will make electronic consent more and more commonplace. Facing this new reality, we must learn how this impacts each stakeholder.